By Chris Wack

 

Cabaletta Bio shares were up 15% to $13.16 on Tuesday after the company said its second Investigational New Drug application for CABA-201 has been cleared by the U.S. Food and Drug Administration for a Phase 1/2 study in patients with active idiopathic inflammatory myopathy.

The stock hit its 52-week high of $13.34 on May 3, and is up 623% in the past 12 months.

The company said it plans to begin a Phase 1/2 clinical trial of CABA-201 for the treatment of six patients with dermatomyositis, six patients with anti-synthetase syndrome, and six patients with immune-mediated necrotizing myopathy, all in separate parallel cohorts.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

May 16, 2023 13:27 ET (17:27 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cabaletta Bio Charts.
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cabaletta Bio Charts.